1.Effect of Shengmai Chenggu Prescription in Preventing Endothelial Cells from Endotoxin -Induced Damage
Chuanyi XU ; Yueguang FAN ; Wei HE ; Haibin WANG ; Hao YUAN
Traditional Chinese Drug Research & Clinical Pharmacology 1993;0(04):-
Objective To observe the effect of Shengmai Chenggu Prescription (SCP) on the damage of endothelial cells (EC) induced by endotoxin. Methods EC obtained from rabbit's aorta were cultured and were treated with endotoxin and serum containing SCP respectively. Histological changes and function of the cultured cells were observed under light microscope and electron microscope and with MTT method . Results Endotoxin could result in the pathologic injury of cultured EC and inhibit the proliferation of the cells. Serum containing SCP could increase the activity of EC and promote its proliferation. Conclusion SCP can protect endothelial cells from damage induced by endotoxin.
2.Investigation on Methylation of Runx3 Gene in Patients with Chronic Atrophic Gastritis
Chunna ZHAO ; Lili XIAO ; Bei WANG ; Yueguang WEI
Chinese Journal of Gastroenterology 2016;21(8):470-473
Background:Chronic atrophic gastritis(CAG)is a kind of chronic gastritis with atrophic changes of gastric mucosa. The studies on peripheral blood biomarkers in CAG are rare. Aims:To investigate the methylation of peripheral blood CpG sites in Runx3 gene promoter region in CAG patients. Methods:Eighty-two mild CAG patients,73 moderate to severe CAG patients from June 2013 to May 2014 at Daqing Oilfield General Hospital were enrolled,and 45 patients with normal gastric mucosa were served as controls. The methylation of CpG sites in Runx3 gene promoter region was measured by MALDI-TOF-MS. mRNA expression of Runx3 was determined by fluorescent quantitative PCR,and the protein expression of Runx3 was determined by Western blotting. Results:Compared with the control group and mild CAG group,methylation levels of CpG13,CpG14 and CpG15 sites in Runx3 gene promoter region were significantly increased in moderate to severe CAG group(P < 0. 05),the mRNA and protein expressions of Runx3 were significantly decreased( P < 0. 05). No significant differences in methylation of CpG sites in Runx3 gene promoter region and mRNA and protein expressions of Runx3 were found between mild CAG group and control group( P >0. 05 ). Conclusions:The hypermethylation of peripheral blood CpG13,CpG14 and CpG15 sites in Runx3 gene promoter region can inhibit the expression of Runx3 in CAG patients,and can be used potentially as the biomarker for clinical staging of CAG.
3.One case report of successful treatment of severe myocarditis mimicking acute myocardial infarction by intra-aortic balloon counterpulsation
Guizhi YIN ; Dadong ZHANG ; Wei HU ; Qiang YU ; Yueguang CHEN ; Jianfeng XU ; Xian JIN ; Jun GU ; Jian DONG ; Dongmei GUI
Journal of Shanghai Jiaotong University(medical Science) 2010;30(1):116-117
An old male patient visited the hospital due to shortness of breath and palpitation for 6 h, with fever 3 days before and pump failure at admission. Having no risk factor of coronary diseases such as hypertension, diabetes mellitus and obesity, with ST-T changes and abnormal Q wave on ECC, the signs were compatible with those of acute anterior wall myocardial infarction, while the characteristics of cardiac biomarkers ( significant increase in Troponin I and creatine kinase's isoform, and normal creatine kinase) were not in accordance with those of acute myocardial infarction. Emergency angiography was performed, which indicated normal coronary artery, normal pulmonary artery and global systolic dysfunction of left ventricle. The diagnosis of acute severe myocarditis was established, and intra-aortic balloon pump (IABP) was employed to provide hemodynamic support. Severe myocarditis mimicking acute myocardial infarction may be fatal, and can be easily misdiagnosed. Careful analysis of clinical manifestations, early diagnostic angiography and possible IABP placement are important for the successful treatment.
4.Effects of tirofiban application time on middle-term clinical prognesis in patients with acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention
Jun GU ; Wei HU ; Hongbing XIAO ; Xiaodi FENG ; Xian JIN ; Qiang YU ; Guizhi YIN ; Ping GUAN ; Chengjun CHEN ; Yueguang CHEN ; Dadong ZHANG
Chinese Journal of Postgraduates of Medicine 2008;31(25):20-22
Objective To investigate the effects of tirofiban application time on middle-term clinical prognosis in patients with acute ST segment elevation myocardial infarction (STEMI)treated by primary percutsneous coronary intervention (PCI). Methods The study of tirofiban was carried out in 50 patients with STEM[in cardiology department from January to December 2006. Twenty-nine patients were randomized to receive tirofiban after PCI for 24 - 36 hours(short time group, STG) and 21 patients for 48 - 72 hours (long time group,LTG). Clinical characteristics, angiography data, main adverse cardiovascular events (MACE) and coronary restenosis rate in 6-month follow-up of the two groups were. compared. Results Follow-up data showed that there was less intractable angina pectoris (14.3% vs 24.1%, P< 0.05) in LTG. But there was no significant difference in coronary restenosis rate between two groups. Conclusion Long time application of tirofiban following PCI in patients with STEMI could improve middle-term clinical prognosis by alleviating the incidence of intractable angina pectoris.
5.Analysis of influencing factors on re-entry of HBV DNA reactive blood donors
Mingjun CHEN ; Yifang WANG ; Lumin YAN ; Yueguang WEI ; Tiantian TU ; Lei ZHAO ; Yonglei LYU
Chinese Journal of Blood Transfusion 2022;35(2):183-185
【Objective】 To explore the factors affecting NAT reactive blood donors re-entry, so as to provide data support for formulation of scientific and reasonable strategy. 【Methods】 The basic data and laboratory test results of 174 NAT reactive returning blood donors from January 2019 to August 2021 were collected and statistically analyzed by logistic regression. 【Results】 Among 174 HBV DNA reactive blood donors applying for re-entry, 81 (46.6%) were eligible for re-entry. Blood donation type and deconstructed Ct value were independent influencing factors of blood donors’ re-entry (P<0.05). The Ct value of minipool and deconstruction test showed significant affection on the re-entry (P<0.05). Donors with minipool-Ct-value exceeding deconstructed-Ct-value had a low likelihood of success with re-entry(P>0.05). No significant difference was observed in Ct values of deconstruction test, first re-entry test and second re-entry test (P<0.05). 【Conclusion】 In view of the low re-entry rate of NAT reactive blood donors, it is necessary to establish a set of safety criteria to lessen workloads. Donors with exceeding minipool-Ct-values, repeat reactive by two NAT reagents, failure in the first re-entry test are suggested to be deferred permanently.